Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CB-010 · 1 trial · 7 indications
Incidence of adverse events defined as dose-limiting toxicities with onset within 28 days after CB-010 infusion.
The primary endpoint is objective response rate.
| Arm | Type | Description |
|---|---|---|
| Dose Escalation of CB-010 | EXPERIMENTAL | Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion. |
| Expansion of CB-010 | EXPERIMENTAL | Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion. |
| Name | Type | Description |
|---|---|---|
| CB-010 | GENETIC | CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
Inclusion Criteria: * Age greater than or equal to 18 at the time of enrollment * Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care * Eastern Cooperative Oncology Group performance status 0 or 1 * Adequate hematologic, renal, liver, cardiac and pulmona...